Wockhardt Limited has informed stock exchanges about receiving a GST demand order of ₹90.23 lakhs from tax authorities for the financial year 2019-20. The pharmaceutical company disclosed this development under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

GST Demand Order Details

The company received the tax demand order dated December 26, 2025, from the Superintendent, Central GST Range-11, Division-III, Ghaziabad. The total demand amount includes both the principal tax liability and penalties imposed by the authorities.

Nature of GST Violation

The demand has been raised due to adjustment of GST amount in the returns filed for FY 2019-20. According to the company's disclosure, the issue stems from excess GST paid during earlier years, which required adjustments in the subsequent financial year returns. The demand arose as part of the regular yearly assessment under current GST provisions.

Company's Response and Impact Assessment

Wockhardt Limited has expressed its disagreement with the demand order and announced plans to file an appropriate appeal against the tax authorities' decision. The company emphasized that this demand order will have no material impact on its financial position, operations, or other business activities.

The pharmaceutical company clarified that the GST demand emerged through routine assessment procedures and would not affect its ongoing operations. Management has assured stakeholders that necessary steps are being taken to contest the order through proper legal channels.

Regulatory Compliance and Disclosure

The company acknowledged a delay in making this disclosure to the stock exchanges, attributing it to an inadvertent administrative oversight. The disclosure was made upon realization of the omission, ensuring compliance with regulatory requirements.

Wockhardt Limited has confirmed that this intimation is also available on the company's official website at www.wockhardt.com , maintaining transparency with all stakeholders regarding this regulatory development.

Wockhardt has achieved a significant regulatory milestone as the European Medicines Agency (EMA) granted accelerated assessment designation to its novel antibiotic WCK 5222 (combination of Zidebactam 1g + Cefepime 2g). The company announced this development through a regulatory filing on December 31st, following a pre-submission meeting with the EMA review team.

Accelerated Assessment Details

The accelerated assessment designation reflects EMA's recognition that WCK 5222 has the potential to address unmet medical needs by providing effective therapeutic options for serious and life-threatening infections. The drug specifically targets multi-drug-resistant (MDR) and extremely drug-resistant (XDR) Gram-negative pathogens.

Approved Indications

The EMA has recognized WCK 5222's potential across multiple serious infection categories. The drug is designed to treat complicated urinary tract infections including pyelonephritis, hospital-acquired pneumonia including ventilator-associated pneumonia, and complicated intra-abdominal infections. Additionally, it addresses bacteraemia occurring in association with these conditions and treats infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.

Historic Achievement for Indian Drug Discovery

WCK 5222 represents the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorization. This milestone reflects the advancement of India-initiated global antimicrobial innovation efforts and demonstrates the growing capabilities of Indian pharmaceutical companies in developing internationally recognized therapies.

Wockhardt's Antibiotic Innovation Portfolio

Wockhardt has maintained its focus on antibiotic innovation for over 27 years, developing a robust pipeline of six antibiotics at various stages of clinical development and commercialization. All antibiotics in the pipeline have received Qualified Infectious Disease Product (QIDP) designation from the US FDA, with three already approved for clinical use and two more in final development stages. The company employs approximately 2,900 people across 27 nationalities, with 77% of global revenues generated from international businesses.